ArticleBlood and lymphatic cancer : targets and therapy2025
Serum ATIC Expression as a Novel Diagnostic and Prognostic Biomarker in Multiple Myeloma Patients.
Article in Blood and lymphatic cancer : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The study was constructed for investigating the serum expression levels of ATIC with multiple myeloma (MM) patients and its potential clinical value as a biomarker, and analyzing its association with disease stage, treatment response, genetic characteristics and prognosis. Patients and Methods: The serum concentrations of ATIC were assessed in 186 MM patients and 201 healthy controls via ELISA, and the diagnostic efficacy was evaluated through ROC curve analysis. Correlation analysis was conducted based on clinical parameters, including common comorbidities, clinical stages, laboratory indicators, disease status, treatment response level, and pathological characteristics. The prognostic relevance of serum ATIC levels in MM patients was assessed using Kaplan-Meier survival analysis. Results: Serum ATIC levels showed a significant upregulated in MM patients (median = 38.26 ng/mL) compared to healthy controls group (median = 16.98 ng/mL) (p < 0.0001). Newly diagnosed MM (NDMM) patients showed higher ATIC levels (median = 46.73 ng/mL). Results from ROC curve analysis showed that ATIC had a good diagnostic performance (AUC = 0.720, p < 0.0001). ATIC levels decreased with treatment response, and the Remission Group (R group) exhibited a notable decrease than the Active Disease Group (AD group) (p < 0.05). Higher R-ISS staging was associated with elevated ATIC levels (p < 0.05). Positive correlations were found between serum ATIC levels and ESR (p = 0.029), β2-MG (p = 0.035), GLO (p = 0.044), UA (p = 0.037), abnormal FISH results (p = 0.02), as well as poor prognosis. Notably, MM patients with diabetes had lower ATIC levels than those without diabetes (p = 0.004). Conclusion: This study found that serum ATIC expression levels were significantly upregulated in MM patients, which is closely related to comorbidities, disease progression, renal dysfunction, and poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.